In the first half of the year, medical and health investment and financing slowed down, and these segments are still sought after

Recently, industry data statistics show that the overall investment and financing of the medical and health industry in the first half of 2022 has slowed down
.

In the first half of 2022, the total disclosed transaction amount reached 25.
4 billion yuan, the number of transactions was 210, and the average single disclosed transaction amount was about 160 million yuan
.

However, some segments such as oncology, rehabilitation, ophthalmology, genetic testing, artificial intelligence and other investment areas are still sought after
.

Among the more than 200 transactions in the first half of the year, many focused on tumors, which are currently in a segment of severe clinical needs and urgently need to break through more technologies
.

For example, in May, anti-tumor drug developer Maitong Biologics announced the completion of a round of financing, the company is mainly engaged in the development of new small molecule targeted anti-tumor drugs with metabolic enzymes related to tumorigenesis as the target, etc.
, and has two research and development projects of IDH gene mutation and tumor, ME3 and pancreatic duct cancer, providing users with anti-tumor drugs and other services
.

For example, on March 18, Conway Bio announced the completion of nearly 200 million yuan A round of financing
.

The company focuses on the research and development and commercialization
of new drugs for tumor immunotherapy.

This round of financing will be used to accelerate the clinical trial of TLR7 agonist CAN1012, which is being carried out simultaneously in China and the United States, using different combination drug regimens, and the product development of multiple follow-up global innovation pipelines, and it is expected that a number of innovative drug projects with new targets and mechanisms will be submitted and clinical trials will be submitted and clinical trials
launched in China and the United States this year.

According to the data of China Health Yearbook, from 2015 to 2020, the industry size of China's ophthalmic medical service market has increased from 50.
71 billion yuan to 112.
57 billion yuan, and it is expected to reach 256.
31 billion yuan
in 2024.

In recent years, the ophthalmology track is also the focus of attention in the investment market, especially the rise of private eye hospital financing, with the help of capital to accelerate large-scale expansion
.

For example, in the first half of 2022, Ho Ophthalmology and Puri Ophthalmology landed on the GEM and ran a race with Aier Ophthalmology
.

As the foundation of precision medicine, genetic testing promotes tumor treatment and immunotherapy, but also accelerates drug research and development, provides a scientific basis for clinical drugs, and the prospects of the industry are promising
.

The capital market's emphasis on genetic testing is also increasing, and in the first half of this year, a number of domestic companies in the field of genetic testing announced the completion of financing, including many loss-making companies
.

For example, on the evening of May 16, the news of the Shanghai Stock Exchange showed that the IPO of the Shihe Gene Science and Technology Innovation Board had been accepted, and the company planned to raise 1.
55 billion yuan
.

According to reports, the company intends to adopt the fourth set of listing standards
.

Shihe Gene is committed to the clinical transformation and application of high-throughput gene sequencing technology, mainly for tumor patients to carry out genetic testing, precision medication, auxiliary diagnosis, tumor early screening, etc.
, the company has been in a state of
loss for a long time.

In addition, artificial intelligence technology is highly anticipated by the industry, and has experienced ten years of continuous investment, and now the investment valuation has returned to rationality
.

Among them, the main scene of intelligent medical treatment is still valued by the capital market, for example, on February 21, Dekang Medical announced the completion of a 500 million yuan B round of financing, after this round of financing, Dekang Medical will accelerate the construction of new production bases, solve the problem of insufficient existing production capacity, and continue to expand sales, as well as invest in the research and development of new orthopedic materials and the next generation of digital orthopedics, in order to continuously introduce new products to maintain its innovation first-mover advantage
.

For example, in June, the pharmaceutical machine vision inspection company "Aocheng Intelligence" received a Pre-A round investment of 15 million yuan; "Sugar Ji Medical" completed nearly 100 million yuan of B round financing, etc.
, and the financing of the medical track has not decreased
as a whole.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.